Endoscopic transcecal appendectomy for the treatment of low-grade appendiceal mucinous neoplasm

Zhijie Jiang1, Bing Hu2, Hui Gong3

  • 1West China School of Clinical Medicine, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

Insights

Endoscopic transcecal appendectomy (ETA) offers a minimally invasive alternative for resecting appendiceal mucinous neoplasms. This novel approach allows complete lesion removal while preserving the ileocecal valve and preventing postoperative appendicitis.

Area of Science:

  • Gastroenterology
  • Surgical Innovation

Background:

  • Appendiceal lesions, primarily inflammatory, can cause abdominal pain.
  • Neoplastic appendiceal lesions, such as appendiceal mucinous neoplasms (AMNs), are uncommon but require management.
  • Traditional management for appendiceal lesions involved surgical appendectomy.

Purpose of the Study:

  • To present endoscopic transcecal appendectomy (ETA) as a novel, minimally invasive alternative for managing low-grade appendiceal mucinous neoplasms (AMNs).
  • To demonstrate the feasibility and efficacy of ETA in completely resecting appendiceal lesions.

Main Methods:

  • Endoscopic transcecal appendectomy (ETA) was performed for a patient with an appendiceal lesion.
  • The procedure involved full-thickness resection, mesoappendix and appendicular artery dissection, and defect closure.
  • A second endoscope was used for continuous dissection during the procedure.

Main Results:

  • The patient recovered and was discharged following improvement.
  • A 6-month follow-up colonoscopy confirmed successful healing of the resection site without complications.

Conclusions:

  • Endoscopic transcecal appendectomy (ETA) is a viable alternative for appendiceal lesions not amenable to polypectomy and for patients who are candidates for surgical appendectomy.
  • ETA offers advantages over traditional surgery, including maximum preservation of the ileocecal valve and intestine, no abdominal scarring, and avoidance of surgical incision-related adverse events.